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Abstract
Background: The frequency of E-cadherin germline mutations in countries with different incidence rates for gastric
carcinoma has not been well established. The goal of this study was to assess the worldwide frequency of CDH1
germline mutations in gastric cancers coming from low- and high-risk areas.
Methods: English articles using MEDLINE access (from 1998 to 2011). Search terms included CDH1, E-cadherin,
germline mutation, gastric cancer, hereditary, familial and diffuse histotype.
The study included all E-cadherin germline mutations identified in gastric cancer patients; somatic mutations and
germline mutations reported in other tumors were excluded.
The method of this study was scheduled in accordance with the “PRISMA statement for reporting systematic
reviews and meta-analyses”. Countries were classified as low- or middle/high risk-areas for gastric carcinoma
incidence. Statistical analysis was performed to correlate the CDH1 mutation frequency with gastric cancer
incidence areas.
Results: A total of 122 E-cadherin germline mutations have been identified; the majority (87.5%) occurred in
gastric cancers coming from low-risk areas. In high-risk areas, we identified 16 mutations in which missense
mutations were predominant. (68.8%). We verified a significant association between the mutation frequency and
the gastric cancer risk area (p < 0.001: overall identified mutations in low- vs. middle/high-risk areas).
Conclusions: E-cadherin genetic screenings performed in low-risk areas for gastric cancer identified a higher
frequency of CDH1 germline mutations. This data could open new approaches in the gastric cancer prevention
test; before proposing a proband candidate for the CDH1 genetic screening, geographic variability, alongside the
family history should be considered.
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Background
CDH1 germline mutations are associated with the devel-
opment of the autosomal cancer syndrome namely Her-
editary Diffuse Gastric Cancer (HDGC) [1,2]; about
25-30% of families fulfilling the clinical criteria for
HDGC established by the International Gastric Cancer
Linkage Consortium (IGCLC) have constitutional altera-
tions of the CDH1 gene [3]. CDH1 germline mutations
can also be identified in sporadic early onset GC
(EOGC) in less than 4% of patients 35 years of age at
the time of diagnosis, presenting as de novo mutations
[4].
Different patterns of CDH1 germline mutations have
been described as truncating, deletion, insertion, splice
site, non sense, silence, and at last, missense alterations
[5].; for CDH1 non-missense mutations, the penetrance
rate is high, with an estimated risk of > 80% [3]., in
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any medium, provided the original work is properly cited.missense mutation carriers, the estimated cancer-risk is
unknown. CDH1 missense mutations are rather fre-
quently detected in HDGC and in EOGC, and they can
be classified as neutral or pathogenic variants [6].
The worldwide incidence of gastric carcinoma is
extremely heterogeneous and the causes of these differ-
ences are still unclear; it has been reported that GC pre-
sents different characteristics considering tumors
coming from low- and high-risk area [7]. In GC patients
coming from high-risk areas environmental factors, as
specific foods, are more probably associated with the
gastric carcinogenesis [8,9] in which genetic factors, as
CDH1 or TP53 germline mutations, are very rarely iden-
tified [10-15]. To assess the CDH1 germline mutation
frequency in low- and high-risk areas for GC, we
reviewed all E-cadherin constitutional alterations identi-
fied from 1998 to date, considering the worldwide geo-
graphic distribution. We focused on low- and high-risk
areas of gastric carcinoma in particular.
Methods
Study accuracy and approach
The accuracy of this systematic review and meta-analysis
was assessed using the checklist of items in accordance
with the “Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) statement” [16].
In particular, we scheduled this systematic review and
meta-analysis as follows: a) Identification: to assess the
CDH1 germline mutation frequency in different risk areas
for GC; b) Screening: to search all identified CDH1 germ-
line mutations, as well as in patients with DGC as in
asymptomatic carriers; c) Eligibility: to include all data
reported in an accessible source bank (the National Library
of Medicine’s MEDLINE database); d) Included: to analyse
the obtained results with statistical analysis (Figure 1).
Study population
In this study we considered all countries in which an
independent CDH1 genetic screening has been per-
formed, aiming for germline mutation search.
We subdivided the world areas in two groups: low
(group A) and middle-high incidence (group B) areas,
considering the GC incidence data reported by Ferlay J.
and Colleagues [17]. Among group A, we identified
these countries: USA, Spain, France, Ireland, Canada,
United Kingdom, New Zealand, Germany, Finland, Paki-
stan, Sweden, the Netherlands, Austria and Iran. This
g r o u pa l s oi n c l u d e ds o m ec a s e sd e f i n e do n l ya s“Eur-
opean” and without specific ancestry. We excluded that
this part is comes from the European area with middle-
high GC risk (as North of Portugal, Central Italy, and
Eastern Europe). Group B includes these zones: Italy
(Tuscany), Portugal (North), Japan, China, Korea, South
America, Lithuania and Poland.
CDH1 germline mutation search and selected articles
We revised all CDH1 germline mutations reported in
MEDLINE from March 1998 to November 2010,
through analysis of original reports and reviews of the
literature edited in the English language. Moreover, we
also included data from two international workshops of
the IGCLC (in 1999 and in 2010) [2,3]. Whenever suffi-
cient, we also considered information obtained from
abstract in the English language with the main text edi-
ted in other languages; a total of 156 papers were
selected for this study. The reported CDH1 constitu-
tional alterations are defined as truncating, deletion,
insertion, splice site, non-sense, and missense mutations
(Table 1); we grouped these mutations as non-missense
(truncating, deletion, insertion, splice site and non
sense) or missense mutations. This study excluded all
CDH1 somatic mutations identified in gastric carci-
noma, and the germline alterations found in primary
lobular breast carcinoma as well as in mucinous colon
cancer. We considered also mutations namely in review
papers as “unpublished results” [5,18].
We used the following search terms to search all
reports, reviews and databases: E-cadherin; CDH1 gene;
germline mutation, and genetic screening; HDGC, and
IGCLC; familial GC; diffuse histotype; Maori kindred,
prophylactic gastrectomy.
Assessment of risk bias
We also evaluated the possibility that the available data
is biased; in particular, we considered two kinds of pos-
sible bias: a) in case selection, specifically by the litera-
ture reviewer and b) from literature data. Point a) was
Figure 1 Flow diagram of study selection and information
through different phases of the systematic review and meta-
analysis. (The diagram was structured in accord with the Digestive
Disease Week; United European Gastroenterology Week and with
the PRISMA statement)
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Page 2 of 10Table 1 CDH1 germline mutations detected to date
Reference CDH1 mutation Exon/Intron Mutation Type Ancestry
[19] 5’UTR(-117)G > A Promotor 5’UTR substitution USA (1)
[19] 5’UTR(-71)C > G Promotor 5’UTR substitution USA (1)
[4] -63 C > A Promotor 5’UTR substitution Italy (1)
[20] Del 5’UTR-ex 1 Promotor Deletion Spain (1)
[20] del ex 1-2 Exon 1-2 Deletion Ireland (1), Canada (1) Lithuania (1)
[5] 2 T > C Exon 1 Missense Unknow (1)
[21] 3 G > C Exon 1 Nonsense Canada (1)
[19] 41delT Exon 1 Deletion USA (1)
[22] 45insT Exon 1 Insertion UK (1)
[5] 46insTGC Exon 1 Insertion Unknow (1)
[19] 48 + 5 G > C Intron 1 Splice Site USA (1)
[19] 48 + 15 C > G Intron 1 Splice Site USA (1)
[18,23,24] 49-2A > G Intron 1 Splice Site Europe (1), UK (1), Ireland (1)
[25] 53delC Exon 2 Deletion Europe (1)
[23] 59 G > A Exon 2 Non sense UK (1)
[26] 70 G > T Exon 2 Non sense USA (1)
[27] 185 G > T Exon 3 Missense Japan (1)
[28] 187 C > T Exon 3 Non sense USA (1)
[1] 190 C > T Exon 3 Non sense New Zealand (1)
[29] 283 C > T Exon 3 Non sense France (1)
[18] 353 C > G Exon 3 Missense Europe (1)
[30] 372delC Exon 3 Deletion Germany (1)
[31] 377delC Exon 3 Deletion Unknow (1)
[32] 382delC Exon 3 Deletion Europe (1)
[19] 388 + 26 C > T Intron 3 Splice Site USA (1)
[31] 515 C > G Exon 4 Missense Unknown (1)
[33] 525 C > G Exon 4 Missense Finland (1)
[6] 532-18 C > T Intron 4 Splice site UK (1), Portugal (1)
[26] 586 G > T Exon 5 Non sense Europe (1)
[32] 531 + 1 G > A Intron 5 Splice site Europe (1)
[34] 531 + 2 T > A Intron 5 Splice site France (1)
[35] 641 T > C Exon 5 Missense Europe (1)
[4] 670 C > T Exon 5 Missense Italy (1)
[18] 715 G > A Exon 6 Missense Europe (1)
[36] 731A > G Exon 6 Missense Korea (1)
[5] 753insG Exon 6 Insertion Unknown (1)
[31] 808 T > G Exon 6 Missense Unknown (1)
[22] 832 G > A Exon 6 Splice site Pakistan (1)
[37] 833-2A > G Inton 6 Splice site USA (1)
[32] 892 G > A Exon 7 Missense Europe (1)
[21,38] 1003 C > T Exon 7 Non sense Sweden (1), Canada (2)
[1] 1008 G > T Exon 7 Splice site New Zealand (1)
[22,39] 1018A > G Exon 8 Missense Europe (1), China (1)
[5] 1023 T > G Exon 8 Nonsense Unknown (1)
[21] 1063delT Exon 8 Deletion Canada (1)
[32] 1064insT Exon 8 Insertion UK (1)
[18] 1107delC Exon 8 Deletion Spain (1)
[40] 1118 C > T Exon 8 Missense Italy (1)
[32,41] 1134del8ins5 Exon 8 Deletion/Insertion Netherlands (1)
[18,34] 1137 G > A Exon 8 Splice site Europe (2)
[26] 1137 + 1 G > A Intron 8 Splice site USA (1)
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[32,42] 1212delC Exon 9 Deletion Europe (1), USA (1)
[32] 1226 T > C Exon 9 Missense Europe (1)
[43] 1243A > C Exon 9 Missense Japan (1)
[21] 1285 C > T Exon 9 Missense Canada (1)
[32] 1226 T > C Exon 9 Missense Europe (1)
[44] 1306_1303insA, 1306_1307delTT Exon 9 Del/Ins Austria (1)
[18] 1391-1392delTC Exon 10 Deletion Europe (1)
[36] 1460 T > C Exon 10 Missense Korea (1)
[45] 1466insC Exon 10 Insertion UK (1)
[22] 1472insA Exon 10 Insertion UK (1)
[32] 1476delAG Exon 10 Deletion Europe (1)
[26] 1487del7 Exon 10 Deletion New Zealand (1)
[46] 1507 C > T Exon 10 Non sense China (1)
[25] 1565 + 1 G > T Intron 10 Splice site New Zealand (1)
[25] 1565 + 2insT Intron 10 Insertion USA (1)
[26] 1588insC Exon 11 Insertion USA (1)
[47] 1610delC Exon 11 Deletion Spain (1)
[48] 1619insG Exon 11 Insertion Germany (1)
[31] 1682insA Exon 11 Insertion Ireland (1)
[25] 1710delT Exon 11 Deletion USA (1)
[28] 1711insG Exon 11 Insertion USA (1)
[32] 1711 + 5 G > A Intron 11 Splice site Europe (1)
[49] 1774 G > A Exon 12 Missense Sweden (1)
[32] 1779insC Exon 12 Insertion Europe (1)
[21,25,28] 1792 C > T Exon 12 Non sense UK (1)
[31] 1795A > T Exon 12 Missense Unknown (1)
[32] 1779insC Exon 12 Insertion Europe (1)
[6] 1849 G > A Exon 12 Missense USA (2)
[31] 1876 T > A Exon 12 Missense Unknown (1)
[6,18,41] 1901 C > T Exon 12 Missense/splice site UK (1), New Zealand (1), Portugal (1)
[31] 1913 G > A Exon 12 Nonsense Spain (1)
[19] 1937-13 T > C Intron 12 Splice Site USA (1)
[32] 2061delTG Exon 13 Deletion Europe (1)
[37] 2064delTG Exon 13 Deletion USA (1)
[1,18] 2095 C > T Exon 13 Non sense New Zealand (1), China (1)
[21] 2161 C > G Exon 13 Splice site Canada (1)
[31] 2164 + 5 G > A Exon 14 Splice site Unknwon (1)
[20] del 14-16 Ex 14-16 Deletion Europe (1)
[32] 2195 G > A Exon 14 Missense Europe (1)
[31] 2245 C > T Exon 14 Missense Colombia (1)
[50] 2269 G > A Exon 14 Missense Portugal (1)
[51] 2275 G > T Exon 14 Nonsense Iran (1)
[21] 2276delG Exon 14 Deletion Canada (1)
[5] 2287 G > T Exon 14 Nonsense Unknown (1)
[25] 2295 + 5 G > A Intron 14 Splice site Europe (1)
[32] 2310delC Exon 15 Deletion Europe (1)
[31] 2343A > T Exon 15 Missense UK (1)
[1] 2381insC Exon 15 Insertion New Zealand (1)
[31] 2392 G > A Exon 15 Missense Unknown (1)
[37] 2395delC Exon 15 Deletion USA (1)
[48] 2396 C > G Exon 15 Missense Germany (1)
[31] 2398delC Exon 15 Deletion Ireland (2)
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ibility assessment independently and disagreements
between those were resolved by consensus; all partici-
pants confirmed the process for data acquisitions. For
point b), we examined results from the available studies
for clues that suggest there may be missing studies
(namely publication bias) or missing data from the
included studies (namely selective reporting bias).
Statistical analysis
All CDH1 germline mutations were stored in a database,
considering the respective geographical origins. Qualita-
tive data in the 2 groups were expressed as frequencies,
organized into contingency tables, and evaluated with
the [chi]
2 test (Pearson [chi]
2 test or Fisher exact test)
to investigate potential differences. The results were
considered statistically significant for p < 0.05. Statistical
analysis was conducted by using SPSS statistical package
(version 15.0) (SPSS, Chicago, IL).
Results
The majority of selected studies were original reports
We analysed a total of 212 studies; in detail 156 were
excluded because they comprised somatic mutations,
germline mutations in breast or colon cancers,
molecular analyses, prophylactic gastrectomy descrip-
tions and outdated reviews. Instead, the other 56 studies
were included and classified as shown in the flow dia-
g r a m( F i g u r e1 ) .T h em a j o r i t yo ft h es t u d i e sw e r eo r i g i -
nal reports (71.4%), and only the three (5.4%) latest
updated reviews were considered for this study [4,5,54].
Two studies (3.6%) were the results of International
Workshop Consensus Conferences (namely IGCLC),
which delineated the clinical criteria selecting proband
for the CDH1 genetic screening [2,3].
For each included study, we considered the number
and the pattern of the identified CDH1 germline muta-
tions; moreover, we carefully evaluated the ancestry of
mutation carriers.
Selection of countries with different risk area for gastric
carcinoma
Far and Middle Western, European and American coun-
tries performed almost an independent genetic screening
aiming for CDH1 germline mutation search (Figure 2).
The countries that identified at least one germline
CDH1 alteration were the following, a) Far East: China,
Korea, Japan and New Zealand; b) Middle East: Iran and
Pakistan; c) Europe: Italy, Spain, Ireland, the United
Kingdom, Lithuania, Germany, Finland, the Netherlands,
Table 1 CDH1 germline mutations detected to date (Continued)
[19] 2439 + 31 G > A Intron 15 Splice site USA (1)
[52] 2399delG Exon15 Deletion USA (1)
[18] 2440-6 C > G Intron 15 Splice site Europe (1)
[53] 2494 G > A Exon 16 Missense Japan (1)
[20] Del ex 16 Exon 16 Deletion Europe (1)
Figure 2 Worldwide map with the overall CDH1 germilne mutations identified in the different countries. Red and yellow indicate
respectively middle/high- and low- risk area for gastric cancer development.
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Page 5 of 10Sweden, Portugal and Austria; d) America: USA, Canada
and Colombia.
We assembled these countries considering the inci-
dence rates of gastric carcinoma spread and were classi-
fied as: a) low- (group A) and b) middle/high-risk
(group B) area (details are described in method section).
Frequency of CDH1 mutation is associated with specific
gastric cancer risk area
All genetic screenings identified at least 122 CDH1
germline mutations (Table 1); 72.1% of these were non-
missense and 27.9% missense alterations (Table 2). Non-
missense mutations occurred with a frequency of 87.5%
and 5.7%, respectively in groups A and B and missense
alterations were 50% in group A and 32.4% in group B
(Figure 3). Twelve CDH1 mutations, six non-missense
and six missense, were reported without ancestry. 93
CDH1 germline mutations were identified in group A;
17 (18.3%) were missense and 77 (82.7%) non-missense.
In group B, a total of 16 germline mutations have been
reported, from which 11 (68.7%) were missense and 5
(31.3%) non-missense. The overall CDH1 germline
mutation frequency was significantly higher in group A
as well as the rate of non-missense alterations (group A
vs. group B: Fisher exact test c
2 15,872; p < 0.001).
Minimization of risk bias
Point a) Two independent reviewers confirmed the
results crosschecking all data, as well as the number and
the ethnicity of CDH1 germline mutations; results were
routinely discussed in scientific meetings and seminars.
To facilitate the common consultation, all identified
CDH1 alterations were recorded in Table 1. Point b)
The heterogeneity of publications could be a risk bias;
we considered only original reports that were the large
majority of the analysed paper (71.4%), and reviews as
other papers were considered only to confirm the results
from those original reports. In particular, the last review
[5] and one original paper [18] reported some CDH1
germline mutations namely as “unpublished results”,
this could reduce the risk bias related with the “missing
studies”.C o n s i d e r i n gt h e“selective reporting bias” as
the missing data from the included studies, we assessed
that the CDH1 mutations overlapped with the latest
review [5] and with the selected original papers.
Discussion
Incidence of gastric carcinoma
Until recently, gastric carcinoma was the second most
common cancer worldwide, but now, with an estimated
934,000 new cases per year in 2002 (8.6% of new cases),
it is in fourth place behind cancers of lung, breast and
colon and rectum. It is the second most common cause
of cancer death (700,000 deaths annually). Almost two-
thirds of cases occur in developing countries and 42% in
China alone. The geographic distribution of GC is char-
acterized by wide international variations; high-risk
areas include East Asia (China, Japan and Korea), East-
ern Europe, and parts of Central and South America.
Incidence rates are low (< 10 per 100,000 in men) in
Southern Asia, North and East Africa, North America,
Australia, New Zealand and Africa [17,55].
In Europe, GC represents the fifth most common can-
cer, after colon and rectum, breast, lung and prostate,
with an incidence of 149,000 per year and mortality rate
of 116,000. The highest European risk area for GC is
the Eastern zone with an incidence of 70,000 per year
(Belarus area). Portugal and Italy represent one of the
most high-risk European areas for stomach cancer, in
particular, respectively, with incidence in 2008 of 41,100
and in Italy with incidence of 33,400 per year [17]. In
Italy, Tuscany and central regions present a GC mortal-
ity rate of 4,2/10,000 inhabitants (2002 ISTAT-The Ita-
lian National Institute of Statistics).
E-cadherin and diffuse gastric cancer
The CDH1 gene maps to chromosome 16q22.1 and con-
sists of 16 exons that encode a 120-kDa protein called
E-cadherin, which is a member of the transmembrane
glycoproteins family. E-cadherin is expressed on epithe-
lial tissues and is responsible for calcium-dependent
cell-cell adhesion. Functionally, it is critical for establish-
ing and maintaining polarized and differentiated epithe-
lia through intercellular adhesion complexes. Human E-
cadherin is considered an invasion suppressor, and
under-expression of E-cadherin is correlated with the
infiltrative and metastatic ability of the tumor [6].
In 1998 in New Zealand, a country that represents a
low GC risk-area, Guilford and Colleagues identified
firstly in Maori kindred the first CDH1 germline trun-
cating mutation in cases with family history for diffuse
Table 2 Frequencies of missense and non-missense CDH1 germline mutations in group A and B; statistical analysis
reveals a strong association between high CDH1 mutation frequency with low-risk area for gastric cancer
Missense mutations (%) Non-missense mutations (%)
Low Incidence (group A) 17 (50) 77 (87.5)
High Incidence (group B) 11 (32.4) 5 (5.7)
Unknown 6 (17.6) 6 (6.8)
Total 34 (27.9) 88 (72.1)
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countries reported other CDH1 germline mutations in
HDGC or in sporadic EODGC with different ethnicities
[4,54].
The definition of the HDGC syndrome was established
in 1999 by the IGCLC that also delineated the criteria for
the CDH1 genetic screening, as follows: 1) two or more
documented cases of diffuse gastric cancer in 1st/2nd
degree relatives, with at least one diagnosed before the
age of 50, or 2) three or more cases of documented dif-
fuse gastric cancer in 1st/2nd degree relatives, indepen-
dently of age of onset [2]. Subsequently, the last
consensus conference of Cambridge in 2010 [3], modified
the criteria as: a) two GC cases in family, one confirmed
DGC < 50; b) three confirmed DGC cases in 1st or 2nd
degree relatives independent of age; c) age < 40; Corso
and Colleagues recently proposed the cut-off age of onset
at ≤ 35 in sporadic EODGC [4]; d) personal or family his-
tory of DGC and lobular breast cancer, one < 50.
In this study, we reported a total of 122 CDH1 germ-
line mutations, respectively 94 (77%) in group A (low-
risk area) and 16 (13.1%) in group B (middle/high-risk
area) (12-9.9% mutations were without ethnicity
information).
Revising these 122 CDH1 mutations, we observed
some main findings: 1) the overall mutation rate is
lower in group B rather than in group A (13.1% vs. 77%;
p < 0.001); 2) group A shows a higher frequency of
non-missense mutations; moreover, CDH1 non-missense
mutations are extremely lower in group B (5.7%), in
which missense variants are predominant (32.4%) (Fig-
ure 2).
Considering the first point, we stated that CDH1
germline mutations in GC middle/high-risk area are
rather rarely identified respecting to low-risk area; as
reported, in middle/high-risk area the probability to per-
form a CDH1 genetic screening with negative result is
high enough [10-12], in which maybe operates environ-
mental factors.
Summary of evidence: CDH1 mutations and geographic
variability
The abovementioned clinical criteria represents an
important approach in selecting probands for the CDH1
genetic screening. Currently, different modifications
have been appointed at these criteria [2,4,32], evaluating
clinical and molecular results along the international
consensus conferences; so far, the risk area vs. incidence
of gastric carcinoma has never been discussed in these
scientific meetings. We stated that “GC risk area and
incidence” can represent an important emerging factor
that relates strongly to the prognosis and other impor-
tant behaviors of GC patients; ethnicity of GC patients
coming from low- or high-risk areas could be consid-
ered in these criteria in order to identify cases with high
or low-risk mutation carriers in hereditary syndromes.
Information about the ancestry, can improve the accu-
racy of proband selection for the CDH1 genetic screen-
ing; in particular, we can consider GC patients as high
or low-risk mutation carriers respectively in low or
high-risk GC areas whenever the abovementioned cri-
teria is fulfilled. This data verifies that in high-risk areas,
clinical criteria should be applied strictly to cases with a
strong family history for GC in particular when it has
identified very young members.
It is important to stress that geographical variability
represents a novel risk factor for gastric carcinoma, clin-
ico-pathological features and some molecular results can
confirm it. These acknowledgments, like the GC risk-
area, provide important information and can propose
different approaches in clinical practice for GC preven-
tion and treatment.
Molecular features and pathogenicity of E-cadherin
missense mutations
The second consideration of this study is that GC high-
risk area shows a higher frequency of CDH1 missense
mutations; identification of a CDH1 missense alteration
also implicated its functional assessment, because in
vitro and in silico analysis with study of control popula-
tion demonstrates that this mutation can be a novel
polymorphic variant without pathogenic impact. We
also revised the frequencies of CDH1 germline missense
mutations with a pathogenic role that was assessed in
21 CDH1 missense alterations [4,56]; 17 of these showed
a deleterious impact and respectively 5 (29.4%) were
coming from middle/high risk-areas and 12 (70.6%)
from low risk-areas. The pathogenicity of the remaining
Figure 3 The figure shows the distribution of missense and
non-missense CDH1 germline mutations in low-risk area
(group A) and high-risk area (group B). Ancestry information of
group C is unknown.
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of finding a novel pathogenic CDH1 missense mutation
(including also non-missense mutations) is higher in GC
low-risk areas. Very recently, we revised the role of the
CDH1 germline mutation in pathogenesis of sporadic
EODGC; a total of 19 mutations have been reported to
date in this GC group but only six (2.3%) of them did in
fact represent variants with a proven potentially deleter-
ious effect. This predicted pathogenicity was based on
the type of mutation (frameshift) or on the results
obtained from in vitro functional analysis. Five of the six
germline pathogenic CDH1 mutations were detected in
EOGC patients from low or moderate incidence GC
areas, whereas only one arose in a patient from Portugal,
a high incidence GC area. Although CDH1 germline
mutations have been searched for in EOGC patients
from other areas where high incidence rates of GC are
verified, namely in countries like China, Korea, Japan,
and even Italy, no deleterious CDH1 germline variants
have been identified [4].
These results demonstrated that functional assessment
of CDH1 germline missense mutations is mandatory, in
particular in GC high-risk cases that show a higher fre-
quency of unpathogenic missense mutations.
Limitations of the current study
Certainly, this study presents some limitations that
should be discussed, also for further consideration. First,
the CDH1 germline mutation frequency could be
affected by research activity, as publication bias or
access to medical care, considering that some CDH1
variants could be unpublished in MEDLINE; this factor
probably is due to the lack of a CDH1 recorded muta-
tion database. However, MEDLINE is the unique search
engine in which we can access easily and freely; unfortu-
nately we do not have access in confidential and in
unpublished data. However, this bias should be very
small, because we carefully collected all CDH1 muta-
tions recorded in MEDLINE; we also discussed this
point in the “result” section. The second point is that
we do not know precisely in what proportion of cases
CDH1 mutations are identified in low vs. middle/high
risk areas, and if the mutation frequency is related to
the number of screened subjects; moreover, the accuracy
of this study could be affected by the human migrations.
The overall CDH1 mutation number identified to date is
rather low and we are not able to also include this fac-
tor (as ratio between number of mutations vs. number
of screened kindred, migration of population, etc.) risk-
ing to dissipate the statistical value, in the excess of data
stratification. In the specific, we were not able to assess
the quantitative genetic analysis due to the lack of infor-
mation about the impact of environmental factor in
DGC development and about migratory behavior.
Further, if applicable and also considering that the clini-
cal criteria are rather limited, in a larger family collec-
tion, this data could be considered. The third limitation
is that we cannot analyse intestinal GC and other risk
factors, such as environmental agents (i.e. specific diet
habits); however, the aim of t h i ss t u d yi so n l yt oa s s e s s
the frequency of CDH1 germline mutation in DGC, in
which environmental factors are probably less important
than in intestinal hystotype. Moreover, the CDH1 germ-
line or somatic mutations have not reported in intestinal
gastric carcinoma, and for this reason, it was excluded
from this systematic review.
Conclusion
GC patients coming from high-risk areas show a lower
incidence of CDH1 germline mutations when compared
with individuals coming from low-risk areas. The find-
ing that CDH1 mutation frequencies are extremely dif-
ferent in high and low-risk GC zones confirms that
gastric carcinoma presents various clinico-pathologic
and molecular features. This data could also open new
different approaches in the GC prevention test; before
proposing a proband candidate for the CDH1, genetic
screening, geographic variability and family history
should be considered.
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